Kopran
166.09
-1.09(-0.65%)
Market Cap₹807.30 Cr
PE Ratio23.02
IndustryHealthcare
Company Performance:
1D-0.65%
1M-5.88%
6M-18.01%
1Y-44.41%
5Y+46.72%
View Company Insightsright
More news about Kopran
08Aug 25
Kopran Limited Reaffirms Merger Plan with Kopran Laboratories Limited
Kopran Limited's Board of Directors has reaffirmed the merger plan with Kopran Laboratories Limited after reviewing updated documentation and financials. The original scheme approved on March 20 remains unchanged, including the swap ratio. The decision was based on fresh documentation, including a valuation report from Ernst & Young, a fairness opinion from Saffron Capital Advisors, and an auditor's certificate from Khandelwal Jain & Co. The merger structure involves Kopran Laboratories Limited merging into Kopran Limited through a Scheme of Amalgamation Merger by Absorption.
29Jul 25
Kopran Ltd Reports Q1 Results, Announces Major Leadership Changes
Kopran Ltd reported a 3% decrease in Q1 revenue to Rs 135.22 crore and a 32.88% decline in net profit to Rs 7.45 crore. The company announced significant leadership changes, including the appointment of Mr. Chandresh Gunvant Gandhi as Additional Independent Director and Mr. Surendra Somani as Chairman & Managing Director. Mr. Susheel Somani resigned as Non-Executive Director due to ill health. The company also appointed M/s Smita Prabhu & Associates as Secretarial Auditor for five years.
29Jul 25
Kopran Reports Q1 Revenue Decline and Board Restructuring
Kopran Limited experienced a financial downturn in Q1, with revenue decreasing to ₹13,522.00 lakhs and net profit falling to ₹745.00 lakhs. The company's EBITDA and EBITDA margin also declined. Simultaneously, Kopran announced major board changes, including the resignation of Chairman Mr. Susheel G. Somani, appointment of Mr. Surendra Somani as new Chairman & Managing Director, and addition of Mr. Chandresh Gunvant Gandhi as an Independent Director.
15May 25
KOPRAN Reports Q4 Decline in Financials, Declares Dividend
KOPRAN Ltd. released Q4 FY2024 results showing a decline in performance. Revenue decreased 8.60% to ₹1,700.00 crore, EBITDA fell 17.21% to ₹202.00 crore, and net profit dropped 47.85% to ₹97.00 crore compared to Q4 FY2023. Despite the downturn, the company declared a dividend of ₹3.00 per share. Annual figures for FY2024 showed improvement, with revenue up 13.55% and net profit increasing 87.50% year-over-year.
28Apr 25
Kopran's API Unit Passes USFDA Inspection Successfully
Kopran Limited's subsidiary, Kopran Research Laboratories Limited, successfully completed a USFDA inspection at its API unit in Mahad, Maharashtra, with no observations. The surveillance inspection, conducted from April 21 to April 25, 2025, demonstrates the company's commitment to quality standards and regulatory compliance in pharmaceutical manufacturing. This achievement could potentially enhance Kopran's market position and customer trust in the global pharmaceutical industry.
20Mar 25
Kopran Approves Merger with Kopran Laboratories, Strengthening Its Healthcare Portfolio
Kopran Limited's Board of Directors has approved the merger of Kopran Laboratories Limited, a promoter group company. The merger involves a share swap of 100 Kopran Limited shares for every 45 Kopran Laboratories shares. This strategic move aims to consolidate healthcare segments, expand market reach, create manufacturing synergies, and position Kopran as an integrated healthcare and pharmaceutical company. The merger will significantly alter Kopran's shareholding pattern, with promoter stake increasing from 44.46% to 55.36%. The consolidated entity is expected to benefit from operational efficiencies, reduced costs, and enhanced growth prospects in the healthcare sector.
Kopran
166.09
-1.09
(-0.65%)
1 Year Returns:-44.41%
Industry Peers
Sun Pharmaceutical
1,679.10
(+1.21%)
Divis Laboratories
6,621.50
(+0.32%)
Cipla
1,577.60
(+0.52%)
Torrent Pharmaceuticals
3,584.30
(+1.43%)
Dr Reddys Laboratories
1,255.90
(+1.27%)
Mankind Pharma
2,476.60
(+0.87%)
Zydus Life Science
987.65
(+0.31%)
Lupin
1,940.00
(-0.57%)
Alkem Laboratories
5,581.50
(+1.04%)
Aurobindo Pharma
1,101.00
(-0.48%)